M

oderna Therapeutics finally came through on a long-delayed promise: The well-funded, secretive biotech published data in a peer-reviewed journal. But while the disclosure may satisfy some of the company’s skeptics, a messy legal dispute could imperil Moderna’s ability to make money on its work.

First, the data: In a paper published in Cell on Friday, Moderna’s scientists demonstrated that their mRNA vaccine for Zika virus managed to protect mice against infection. All of the mice on placebo succumbed to the virus after 42 days, while nearly all of the mice who got Moderna’s vaccine survived.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy